- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 37/00 - Drugs for immunological or allergic disorders
Patent holdings for IPC class A61P 37/00
Total number of patents in this class: 9046
10-year publication summary
|
356
|
490
|
638
|
658
|
611
|
740
|
695
|
621
|
552
|
219
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
290 |
| Bristol-myers Squibb Company | 4812 |
151 |
| F. Hoffmann-La Roche AG | 7839 |
130 |
| Novartis AG | 10345 |
117 |
| Incyte Corporation | 1060 |
74 |
| Genentech, Inc. | 4070 |
72 |
| Hoffmann-La Roche Inc. | 3696 |
62 |
| Boehringer Ingelheim International GmbH | 4510 |
60 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3334 |
48 |
| Merck Patent GmbH | 5663 |
45 |
| Janssen Pharmaceutica N.V. | 3234 |
42 |
| Takeda Pharmaceutical Company Limited | 2721 |
42 |
| Glaxo Group Limited | 4365 |
40 |
| The Regents of the University of California | 20556 |
38 |
| AstraZeneca AB | 2837 |
38 |
| Glaxosmithkline Intellectual Property Development Limited | 773 |
38 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 677 |
38 |
| Pfizer Inc. | 3371 |
37 |
| Bayer Pharma AG | 1028 |
33 |
| Jiangsu Hengrui Medicine Co., Ltd. | 695 |
32 |
| Other owners | 7619 |